Sui Chengguang, Ma Jianzhong, Chen Qun, Yang Yang
aCancer Research Institute, First Affiliated Hospital, China Medical University bDepartment of Cell Biology, Key Lab of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang cSchool of Sciences, Ningxia Medical University, Yinchuan, China.
Eur J Cancer Prev. 2016 Jul;25(4):288-98. doi: 10.1097/CEJ.0000000000000185.
The susceptibility of secreted frizzled-related protein 2 (SFRP2) methylation in colorectal cancer (CRC) has been studied previously. The aim of this study was to determine the risk sizes and variation trends of SFRP2 methylation in CRC development in Chinese populations. Subgroup meta-analysis and the least-squares curve-fitting method were carried out to analyze the risk of SFRP2 methylation in tissue, feces, and blood detection from 2221 samples, including a total of 1103 cases of CRC, 459 cases of adenoma, 257 cases of polyps, and 402 controls. The data showed that odds ratios (95% confidence intervals) between CRC and controls for tissue, feces, and blood detection were 334.01 (104.42-1068.39), 63.76 (20.62-197.63), and 133.75 (18.32-976.32), respectively. There were also significant differences between tissue and feces or blood as well as between feces and blood methylation frequency. These results showed that the risk size in tissue was much greater than that in feces and that in blood. The results pointed out that three curves in tissue, feces, and blood detection described the variation trends of methylation incidence from the control to polyp, to adenoma and to CRC, and that the variation trend of the risk size of SFRP2 methylation was synchronized with the histological evolution process of CRC. The variation trend of the risk size of SFRP2 methylation incidence is consistent with the histological evolution process of CRC. The susceptibility to SFRP2 methylation is an important biomarker in the study of early diagnosis of CRC and high-risk patients.
此前已对分泌型卷曲相关蛋白2（SFRP2）甲基化在结直肠癌（CRC）中的易感性进行了研究。本研究的目的是确定中国人群中SFRP2甲基化在CRC发生发展中的风险大小及变化趋势。采用亚组荟萃分析和最小二乘曲线拟合方法，对2221份样本（包括1103例CRC、459例腺瘤、257例息肉和402例对照）的组织、粪便和血液检测中SFRP2甲基化的风险进行分析。数据显示，CRC与对照在组织、粪便和血液检测中的比值比（95%置信区间）分别为334.01（104.42 - 1068.39）、63.76（20.62 - 197.63）和133.75（18.32 - 976.32）。组织与粪便或血液之间以及粪便与血液甲基化频率也存在显著差异。这些结果表明，组织中的风险大小远大于粪便和血液中的风险大小。结果指出，组织、粪便和血液检测中的三条曲线描述了从对照到息肉、腺瘤再到CRC的甲基化发生率变化趋势，且SFRP2甲基化风险大小的变化趋势与CRC的组织学演变过程同步。SFRP2甲基化发生率风险大小的变化趋势与CRC的组织学演变过程一致。SFRP2甲基化易感性是CRC早期诊断和高危患者研究中的重要生物标志物。
